ADCV01 / Ever Supreme Bio Tech - LARVOL DELTA

Evaluate the Efficacy and Safety of ADCV01 as an Add-On Treatment for Primary Glioblastoma Multiforme (GBM) Patients (clinicaltrials.gov) - P2 | N=24 | Recruiting | Sponsor: Ever Supreme Bio Technology Co., Ltd. | Trial completion date: Dec 2026 ➔ Dec 2027 | Trial primary completion date: Dec 2026 ➔ Dec 2027

Trial completion date • Trial primary completion date • Brain Cancer • Glioblastoma • Oncology • Solid Tumor • PD-L1

Phase 1b Dose Escalation of 212Pb-ADVC001 and novel 212Pb PET Imaging (TAT-Alpha 2026) - P1/2 | "212Pb-ADCV001 point sources in glass capillary tubes in a water phantom were imaged to determine the system spatial resolution, full width at half maximum (FWHM). Clinical 212Pb-ADVC001 PET imaging of 208Tl gamma pair production confirmed the alpha emission from 212Pb-ADVC001 within PSMA-avid lesions. Phase 2 expansion will assess 212Pb-ADVC001 with novel dosing strategies to optimize clinical outcomes in 3 indications across mCRPC and metastatic hormone-sensitive prostate cancer."

P1 data • Castration-Resistant Prostate Cancer • Dental Disorders • Genito-urinary Cancer • Hormone Sensitive Prostate Cancer • Oncology • Prostate Cancer • Solid Tumor • Xerostomia

Evaluate the Efficacy and Safety of ADCV01 As an Add-On Treatment for Primary Glioblastoma Multiforme (GBM) Patients (clinicaltrials.gov) - P2 | N=24 | Recruiting | Sponsor: Ever Supreme Bio Technology Co., Ltd. | Trial completion date: Dec 2023 ➔ Dec 2026 | Trial primary completion date: Dec 2022 ➔ Dec 2026

Trial completion date • Trial primary completion date • Brain Cancer • CNS Tumor • Glioblastoma • Oncology • Solid Tumor • CD8 • IDH1 • PD-1 • PD-L1

Changsheng: Product and technology transfer revenue will boost operations in the first quarter, which will be better than the same period last year [Google translation] (stock.yahoo) - "Changsheng communicated with the media today. Liu Zhuqi said that its products include dendritic cell vaccine (ADCV01), second-generation dendritic cell vaccine (ADCV02), CIK (cytokine-induced killer cells), new cell therapy Gamma delta T and DC-CIK (dendritic cell combined with cytokine-induced killer cells), etc., after optimization, the gross profit margin is higher and the turnover rate is faster....Changsheng said that the gross profit of ADCV02 increased by 10% compared with the first generation."

Sales • Oncology • Solid Tumor

Evaluate the Efficacy and Safety of ADCV01 as an Add-On Treatment for Primary Glioblastoma Multiforme (GBM) Patients (clinicaltrials.gov) - P2 | N=24 | Recruiting | Sponsor: Ever Supreme Bio Technology Co., Ltd. | Trial completion date: Jun 2022 ➔ Dec 2023 | Trial primary completion date: Dec 2021 ➔ Dec 2022

Trial completion date • Trial primary completion date • Brain Cancer • Glioblastoma • Oncology • Solid Tumor • CD8 • IDH1 • PD-1 • PD-L1

Changsheng, the leader in cell therapy cancer, increased its annual revenue by 479.43% in February (udn.com) - "Changsheng (6712) announced...that its February revenue was 15.65 million yuan, an annual increase of 479.63%, a record high...Changsheng has deployed two major technology platforms for immune cells and stem cells, and is committed to providing diversified cell therapy products...Changsheng continues to promote the clinical trials of new drugs ADCV01..."

Commercial • Oncology